18F-FDG PET/CT 对心脏肿块的诊断与预后评估:一项回顾性研究
该回顾性研究分析了64例患者共65个心脏肿块的18F-FDG PET/CT图像,比较良恶性病变的CT特征和代谢指标。SUVmax 6.75为鉴别良恶性的最佳截断值,诊断灵敏度92.11%、特异度88.89%、准确率90.77%。多因素分析仅SUVmax≥6.715为独立预后因素,中位OS在SUVmax<6.715组为1460天,≥6.715组为342天(P<0.01)。
要点
- SUVmax 6.75是鉴别心脏肿块良恶性的最佳截断值,灵敏度92.11%、特异度88.89%。
- 联合CT特征与SUVmax可优化诊断性能,≥3个CT特征或SUVmax≥6.75时准确率92.31%。
- SUVmax≥6.715是总生存期的独立预后因素,中位OS为342天 vs 1460天。
核心结论
- 18F-FDG PET/CT有助于治疗前心脏肿块的诊断,并可用于发现心外原发或继发肿瘤。
- 18F-FDG PET/CT可为心脏肿块患者提供预后信息,SUVmax显示独立预后价值。
研究设计与样本
- 回顾性分析64例患者共65个心脏肿块的18F-FDG PET/CT图像,其中男性34例、女性30例,平均年龄51.2±17.5岁。
- 比较良恶性病变之间以及原发与继发恶性肿瘤及淋巴瘤之间的CT特征和18F-FDG代谢指标。
- 计算PET/CT鉴别良恶性肿块的诊断价值,并用Cox比例风险模型评估总生存期的潜在独立预测因素。
主要发现
- 良恶性肿块之间多种形态学特征和代谢指标存在统计学显著差异。
- SUVmax 6.75为鉴别良恶性肿块的最佳截断值,灵敏度92.11%、特异度88.89%、准确率90.77%、阳性预测值92.11%、阴性预测值88.89%。
- 以CT特征联合SUVmax≥6.75为标准时,灵敏度76.32%、特异度100.00%、准确率86.15%、阳性预测值100.00%、阴性预测值75.00%。
- 以≥3个CT特征或SUVmax≥6.75为标准时,灵敏度94.74%、特异度88.89%、准确率92.31%、阳性预测值92.31%、阴性预测值92.31%。
- 多因素分析仅SUVmax≥6.715有统计学意义(P<0.01);中位OS在SUVmax<6.715组为1460天,≥6.715组为342天(P<0.01)。
关键数值与推荐
- SUVmax 6.75为鉴别心脏肿块良恶性的最佳截断值,灵敏度92.11%、特异度88.89%、准确率90.77%。
- CT特征联合SUVmax≥6.75时特异度100.00%、阳性预测值100.00%。
- ≥3个CT特征或SUVmax≥6.75时准确率92.31%、阳性预测值92.31%、阴性预测值92.31%。
- SUVmax≥6.715为总生存期的独立预后因素(P<0.01),中位OS为342天 vs 1460天。
临床怎么用
- 对心脏肿块患者治疗前可行18F-FDG PET/CT,以SUVmax 6.75为参考截断值辅助鉴别良恶性。
- 联合CT形态学特征(如≥3个CT特征)与SUVmax可优化诊断性能,减少误判。
- SUVmax≥6.715提示预后较差,可用于风险分层和预后沟通。
局限性
- 本研究为回顾性研究,样本量64例患者、65个心脏肿块。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Correct diagnosis and prognostic assessment of cardiac masses are crucial before therapy. We evaluated the diagnostic and prognostic value of 18F-FDG PET/CT in patients with cardiac masses. METHODS: 18F-FDG PET/CT images of 64 patients with 65 cardiac masses were retrospectively analysed (34 men, 30 women; average age, 51.2 ± 17.5 years). Comparisons of CT features and 18F-FDG metabolic indices between benign and malignant entities, as well as among primary and secondary malignancies and lymphoma, were performed. The diagnostic values of PET/CT for distinguishing benign versus malignant masses were calculated. PET/CT data were further assessed for the predictive value for overall survival (OS) using the Cox proportional hazards model to assess potential independent predictors. Kaplan-Meier curves were generated to assess the value of PET/CT for prognostication. RESULTS: Statistically significant differences in various morphological features and metabolic indices between benign and malignant masses were found. An SUVmax of 6.75 was the optimal cutoff value to differentiate between benign and malignant masses, and the diagnostic sensitivity, specificity, accuracy, positive predictive value, and negative predictive value were 92.11%, 88.89%, 90.77%, 92.11%, and 88.89%, respectively. Taking CT features and SUVmax ≥ 6.75 as a criterion, the values were 76.32%, 100.00%, 86.15%, 100.00%, and 75.00%, respectively; taking ≥ 3 CT features or SUVmax ≥ 6.75 as a criterion, the values were 94.74%, 88.89%, 92.31%, 92.31%, and 92.31%, respectively, indicating optimal diagnostic performance when paired with the anatomic information provided by the CT component. A univariate analysis of OS determined that surrounding tissue infiltration, epicardial infiltration, necrosis, multiple chambers or vessel involvement, distant metastasis, SUVmax, SUVmean, metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were significant predictors of survival. In the multivariate analysis, only SUVmax ≥ 6.715 was significant (P < 0.01). Median OS was 1460 days for SUVmax < 6.715 and 342 days for SUVmax ≥ 6.715 (P < 0.01). CONCLUSION: 18F-FDG PET/CT is helpful in the diagnosis of cardiac masses before treatment and has value in detecting extracardiac primary or secondary tumours. 18F-FDG PET/CT could also be a promising tool to provide prognostic information for these patients, especially SUVmax displaying independent prognostic value.
引用
- Qin C, Shao F, Hu F, et al. 18F-FDG PET/CT in diagnostic and prognostic evaluation of patients with cardiac masses: a retrospective study. Eur J Nucl Med Mol Imaging. 2019. PMID: 31807883. doi:10.1007/s00259-019-04632-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。